MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal
The deal focuses on addressing critical unmet medical needs
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
CSL Seqirus announces strengthened vaccine partnership with UK government
The partnership introduces a world-first flu vaccine and extends the health security pandemic agreement
CPHI Milan introduces new specialist zones
The event runs from 6-8 October 2026 at the Fiera Milano exhibition centre in Rho, Italy
Latest content
Inizio Evoke appoints Brian Gundich as EVP, AI Enablement
Gundich most recently drove enterprise-wide intelligence and operations transformations at Interpublic Group
Read More
Inizio Evoke appoints Jake Vander Linden as President, Media
Vander Linden was previously EVP, Innovation and Advanced Agitation at Moon Rabbit
Read More
Empowering expertise in an age of complexity
Leadership doesn’t always mean having the answers – it means creating the conditions for others to succeed
Read More
From activity to accountability: the omnichannel metrics that pharma leadership actually acts on
How do you prove that omnichannel is working and providing business value?
Read More
Intelligence
Strengthening engagement with HCPs needs deep understanding not digital bombardment
Closing the critical gap between HCPs’ need for information and the pharma industry’s ability to deliver relevant, tailored content
Read More
Cell and gene therapies – moving from niche innovations towards broader clinical use
Looking at the regulatory challenges of cell and gene therapies for serious or life-threatening rare diseases
Read More
Creating a strong patent portfolio through constant communication
Why patenting should not stop at the drug candidate stage – and why coordination between researchers and attorneys is essential for strong protection
Read More
Leading through complexity
Strengthening strategic judgement during uncertainty – exploring the strategic concepts that matter most
Read More
The Amazon reckoning: GLP-1s and the consumer lifestyle shift – why the molecule is no longer enough
Amazon’s entry into the GLP-1 market should be a signal to pharma that it needs to shift focus from molecule to ‘Operating Model’
Read More
Lupus – moving patient care beyond current therapies towards resetting the immune system
Precision medicine is no longer theoretical, but increasingly achievable for people living with lupus
Read More
Blogs
Latest
Using AI Responsibly in CME Outcomes Reporting
October 1, 2026 | Medscape Education|
ICYMI at #AIS2026: using AI in outcomes reporting is a lot like onboarding a research assistant. There’s real efficiency in having the help, and a …
ANTHEM launches Healthy Influence – a new science-led approach to solve healthcare’s attention problem
October 1, 2026 | Resonant Group|Behavioural science, Healthcare PR, healthcare communications
Global healthcare communications consultancy ANTHEM, a Resonant Group company, today announces the launch of Healthy Influence™, its proprietary methodology that applies the science of influence …
Pharma-Exclusive Webinar: Redefining Engagement in the AI Era
September 17, 2026 | Impetus Digital|AI, AI compliance, AI for life sciences, AI for pharma, HCP engagement, HCP training, Impetus Digital, KOL Engagement, Pharma trends, artificial intelligence, kol education, life sciences, patient engagement, pharma AI, webinar
Join Impetus Digital’s pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static programs into high-retention, interactive experiences without enterprise overhead.
The Pulse of AI Innovation: From More Data to Better Care
September 17, 2026 | Medscape Education|
At the European Society of Cardiology (ESC) Congress, two of cardiology’s most influential voices sat down to talk about artificial intelligence at Medscape’s ‘The Pulse …
Governor Josh Stein marks strengthening North Carolina-Ireland trade relationship at Uniphar facility visit
September 16, 2026 | Uniphar|
The event speaker panel, from left to right: Brian Kiefel, Ireland Site Leader & CTO, Honeywell; Christopher Chung, Chief Executive Officer, EDPNC; Tom Scrivener, Group …
The outcomes are already chosen. So when can patients really shape them?
September 29, 2026 | Cuttsy + Cuttsy|Clinical assessment, EU HTA, Joint Clinical Assessment, Joint Scientific Consultation, clinical trial
Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.
The partnership paradox in pharma: Why the best client–agency relationships feel less like business
September 29, 2026 | Emotive|
In MedComms, great client–agency partnerships go far beyond delivering what’s requested, when it’s needed. At their best, they’re built on something deeper – an ambition …
Long-term clinical trial engagement is a behavioural challenge – not just an informational one
September 24, 2026 | Cuttsy + Cuttsy|Behavioural science, Engagement, clinical study, clinical trials, communication, empathy, experience, retention
Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed …
Patients are telling the truth — just not to you
September 21, 2026 | Cuttsy + Cuttsy|Data, Social Listening, clinical trials, patients
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.